{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "Oxaliplatin",
      "fever",
      "hypersensitivity reaction"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "25361599",
  "DateCompleted": {
    "Year": "2016",
    "Month": "12",
    "Day": "13"
  },
  "DateRevised": {
    "Year": "2018",
    "Month": "12",
    "Day": "02"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2014",
        "Month": "10",
        "Day": "30"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1177/1078155214558350"
    ],
    "Journal": {
      "ISSN": "1477-092X",
      "JournalIssue": {
        "Volume": "22",
        "Issue": "2",
        "PubDate": {
          "Year": "2016",
          "Month": "Apr"
        }
      },
      "Title": "Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners",
      "ISOAbbreviation": "J Oncol Pharm Pract"
    },
    "ArticleTitle": "Atypical presentation of fever as hypersensitivity reaction to oxaliplatin.",
    "Pagination": {
      "StartPage": "319",
      "EndPage": "324",
      "MedlinePgn": "319-24"
    },
    "Abstract": {
      "AbstractText": [
        "Oxaliplatin, a third-generation, platinum-based agent is widely used, most commonly in the FOLFOX (5-fluorouracil, leucovorin and oxaliplatin) regimen, which is the first-line therapy in metastatic colorectal adenocarcinoma and adjuvant chemotherapy in stage III colorectal cancer. Platinum-based products are well known for causing hypersensitivity reactions. Fever associated with oxaliplatin-hypersensitivity reactions typically follows a specific pattern. It usually starts during the oxaliplatin infusion or immediately after (within hours instead of days) and happens after several administrations (mean 2-25) with unpredictable clinical presentations. We report a case of oxaliplatin-induced hypersensitivity reaction manifesting as fever but with unusual presentation than the aforementioned features."
      ],
      "CopyrightInformation": "\u00a9 The Author(s) 2014."
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Internal Medicine Residency Program, School of Medicine, University of Connecticut, Farmington, USA Khurana@resident.uchc.edu."
          }
        ],
        "LastName": "Khurana",
        "ForeName": "Arushi",
        "Initials": "A"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Medical Oncology, Roswell Park Cancer Institute, Buffalo, USA."
          }
        ],
        "LastName": "Mitsis",
        "ForeName": "Demytra",
        "Initials": "D"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Internal Medicine Residency Program, School of Medicine, University of Connecticut, Farmington, USA."
          }
        ],
        "LastName": "Kowlgi",
        "ForeName": "Gurukripa N",
        "Initials": "GN"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "School of Pharmacy, University of Connecticut, Farmington, USA."
          }
        ],
        "LastName": "Holle",
        "ForeName": "Lisa M",
        "Initials": "LM"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Neag Comprehensive Cancer Center, University of Connecticut Health Center, Farmington, USA."
          }
        ],
        "LastName": "Clement",
        "ForeName": "Jessica M",
        "Initials": "JM"
      }
    ],
    "PublicationTypeList": [
      "Case Reports",
      "Journal Article"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "England",
    "MedlineTA": "J Oncol Pharm Pract",
    "NlmUniqueID": "9511372",
    "ISSNLinking": "1078-1552"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antineoplastic Agents"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Organoplatinum Compounds"
    },
    {
      "RegistryNumber": "04ZR38536J",
      "NameOfSubstance": "Oxaliplatin"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Aged"
    },
    {
      "QualifierName": [
        "adverse effects"
      ],
      "DescriptorName": "Antineoplastic Agents"
    },
    {
      "QualifierName": [
        "diagnosis",
        "drug therapy"
      ],
      "DescriptorName": "Colonic Neoplasms"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Diagnosis, Differential"
    },
    {
      "QualifierName": [
        "diagnosis"
      ],
      "DescriptorName": "Drug Hypersensitivity"
    },
    {
      "QualifierName": [
        "chemically induced",
        "diagnosis"
      ],
      "DescriptorName": "Fever"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Male"
    },
    {
      "QualifierName": [
        "adverse effects"
      ],
      "DescriptorName": "Organoplatinum Compounds"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Oxaliplatin"
    }
  ]
}